Nexus BioPharma
Nexus BioPharma, Inc. is a preclinical stage biotechnology company developing new therapies and intellectual property for treating obesity and type 2 diabetes. The company focuses on targeting an established metabolic pathway to stimulate weight loss and improve blood chemistry, including lower blood glucose, cholesterol, insulin, insulin resistance, and triglycerides. Their approach involves pharmaceutical activation of this pathway, with promising pre-clinical trial results showing reduced fat mass, increased energy expenditure, and improved blood chemistry. Nexus BioPharma is advancing to pre-IND trials in preparation for FDA human trials, aiming to develop safer and more effective weight loss drugs and expand into additional indications such as diabetes, neurodegenerative diseases, and aging.
Industries
Nr. of Employees
small (1-50)
Nexus BioPharma
JLABS @ TMCx, 2450 Holcombe Boulevard, Suite J, Houston, Texas 77021-2040
Products
Preclinical small-molecule AMPK activators / kinase inhibitors
Investigational orally available small-molecule compounds designed to activate the AMPK metabolic pathway or inhibit kinases (including FYN) to increase energy expenditure and reduce fat mass; currently at preclinical stage with intent to progress to pre-IND and IND-enabling studies.
Preclinical small-molecule AMPK activators / kinase inhibitors
Investigational orally available small-molecule compounds designed to activate the AMPK metabolic pathway or inhibit kinases (including FYN) to increase energy expenditure and reduce fat mass; currently at preclinical stage with intent to progress to pre-IND and IND-enabling studies.
Services
Conducts high-throughput screening, medicinal chemistry, and preclinical pharmacology to identify and optimize small-molecule leads for metabolic indications.
Preparation and planning for regulatory interactions including Pre-IND meetings, IND-enabling study design, and strategy for expedited designation requests.
Partnerships with CROs and external research organizations to conduct screening campaigns, present collaborative data at scientific conferences, and support outsourced experiments.
Conducts high-throughput screening, medicinal chemistry, and preclinical pharmacology to identify and optimize small-molecule leads for metabolic indications.
Preparation and planning for regulatory interactions including Pre-IND meetings, IND-enabling study design, and strategy for expedited designation requests.
Partnerships with CROs and external research organizations to conduct screening campaigns, present collaborative data at scientific conferences, and support outsourced experiments.
Expertise Areas
- Preclinical small-molecule discovery
- Kinase inhibitor development (FYN-targeted)
- AMPK pathway modulation for metabolic disease
- Preclinical pharmacology and animal models
Key Technologies
- High-throughput screening (HTS)
- Transition-state analog chemistry
- Kinase inhibition assays and inhibitor design
- Small-molecule medicinal chemistry
News & Updates
Nexus BioPharma, Inc. announced its selection to become a resident company at the Johnson & Johnson Innovation, JLABS facility at the Texas Medical Center in Houston, Texas, and will relocate its headquarters to Houston as of February 1, 2017.
Nexus BioPharma reached an agreement with TransChem, Inc. to license TransChem’s proprietary transition state chemistry technology for kinase inhibition, which is a significant development in the company's efforts to develop safer and more effective kinase inhibitors for various conditions.
Nexus BioPharma provided a business overview outlining the clinical status of its weight loss product candidate in pre-clinical development, and highlighted near-term milestones including FDA meetings, clinical trials, and potential NASDAQ listing.
Nexus BioPharma, Inc. announced its selection to become a resident company at the Johnson & Johnson Innovation, JLABS facility at the Texas Medical Center in Houston, Texas, and will relocate its headquarters to Houston as of February 1, 2017.
Nexus BioPharma reached an agreement with TransChem, Inc. to license TransChem’s proprietary transition state chemistry technology for kinase inhibition, which is a significant development in the company's efforts to develop safer and more effective kinase inhibitors for various conditions.
Nexus BioPharma provided a business overview outlining the clinical status of its weight loss product candidate in pre-clinical development, and highlighted near-term milestones including FDA meetings, clinical trials, and potential NASDAQ listing.